Glipden-M1

Description

GLIPDEN-M1 contains Glimepiride 1 mg and Metformin 500 mg in tablet form. This combination brings together two oral antidiabetic medicines with complementary actions. Glimepiride stimulates insulin release from the pancreas, while Metformin helps reduce glucose production by the liver and improves insulin sensitivity. Together, they may help improve blood glucose control in adults with type 2 diabetes mellitus when prescribed alongside appropriate diet and exercise.

For related diabetic and cardiovascular formulations, explore the Medhexa Pharma Cardries Biotic range for additional pharmaceutical products and business enquiries.

Therapeutic Segment

Anti-Diabetic Therapy | Type 2 Diabetes Management | Biguanides | Sulfonylureas | Blood Glucose Control

Uses of GLIPDEN-M1

GLIPDEN-M1 may be prescribed as part of an individualized treatment plan for:

• Type 2 diabetes mellitus
• Inadequate blood glucose control with diet and exercise alone
• Patients requiring combination therapy with Glimepiride and Metformin
• Patients who need additional glycaemic control despite treatment with a single oral antidiabetic medicine
• Long-term blood glucose management when combination therapy is considered appropriate

The formulation is intended for type 2 diabetes and should not be used to treat type 1 diabetes or diabetic ketoacidosis.

Key Benefits of GLIPDEN-M1

• Dual-action formulation: Combines Glimepiride and Metformin through complementary mechanisms.
• Blood glucose support: Helps improve glycaemic control in adults with type 2 diabetes.
• Glimepiride 1 mg: Stimulates pancreatic beta cells to release insulin.
• Metformin 500 mg: Helps reduce glucose production by the liver and improves insulin sensitivity.
• Combination convenience: Provides two established oral antidiabetic medicines in one tablet.
• Supports individualized therapy: May be prescribed when combination treatment is clinically appropriate.

How GLIPDEN-M1 Works

Glimepiride belongs to the sulfonylurea class. It stimulates pancreatic beta cells to release insulin. The increased insulin availability helps the body move glucose from the bloodstream into tissues, thereby reducing blood glucose levels.

Metformin belongs to the biguanide class. It primarily reduces glucose production by the liver. It also improves peripheral insulin sensitivity, which helps the body use glucose more effectively.

Therefore, GLIPDEN-M1 combines increased insulin secretion with reduced hepatic glucose production and improved insulin sensitivity.

Common Side Effects of GLIPDEN-M1

Some people may experience side effects, particularly when treatment begins or the dose changes. Possible effects include:

• Nausea
• Diarrhoea
• Abdominal discomfort
• Stomach pain
• Loss of appetite
• Indigestion
• Changes in taste
• Headache
• Dizziness
• Hypoglycaemia

Metformin commonly causes gastrointestinal effects, especially during the early stages of treatment. Glimepiride can cause low blood glucose, particularly when meals are skipped or food intake is insufficient.

Seek medical attention for severe or persistent hypoglycaemia, confusion, loss of consciousness, breathing difficulty or other serious symptoms.

Important Safety Information

Use GLIPDEN-M1 only according to the advice of a qualified healthcare professional.

• Monitor blood glucose regularly as recommended by your diabetes-care team.
• Hypoglycaemia: Glimepiride can cause low blood glucose. The risk may increase when meals are skipped, calorie intake is inadequate, alcohol is consumed or other glucose-lowering medicines are used.
• Maintain regular meals according to your healthcare professional’s advice while taking Glimepiride.
• Kidney function: Metformin requires appropriate assessment of renal function before and during treatment.
• Metformin can rarely cause lactic acidosis, a serious condition. Seek urgent medical attention for severe weakness, unusual sleepiness, breathing difficulty, persistent vomiting or severe abdominal discomfort.
• GLIPDEN-M1 should not be used when Metformin is contraindicated, including severe renal impairment.
• Tell your doctor if you have kidney disease, liver disease, heart failure, severe infection or a history of metabolic acidosis.
• Inform your healthcare professional before undergoing imaging procedures involving iodinated contrast because Metformin may require temporary interruption depending on kidney function and the procedure.
• Long-term Metformin treatment can reduce Vitamin B12 levels in some patients. Healthcare professionals may monitor B12 levels when clinically appropriate.
• Tell your doctor if you have glucose-6-phosphate dehydrogenase (G6PD) deficiency or a history of significant anaemia before using Glimepiride.
• Avoid excessive alcohol consumption because it can affect blood glucose control and may increase the risk of Metformin-related complications.
• Tell your healthcare professional about all prescription medicines, over-the-counter medicines, vitamins and supplements you take.
• Discuss pregnancy or breastfeeding with your healthcare professional before using the medicine.
• Do not stop or change diabetes treatment without medical advice.
• Keep the medicine out of the reach of children.

For additional information about Metformin and its safety considerations, refer to the NHS guidance on Metformin.

Dosage & Administration

Take GLIPDEN-M1 exactly as prescribed by your healthcare professional.

The appropriate dose depends on the patient’s blood glucose levels, previous antidiabetic treatment, kidney function, tolerability and response to therapy.

For immediate-release Glimepiride and Metformin combinations, healthcare professionals individualize the starting dose and adjust treatment according to glycaemic response and tolerability. The exact regimen should follow the approved product information and prescription.

Take the tablet with a meal according to your healthcare professional’s instructions. Taking Metformin with food can help reduce gastrointestinal discomfort, while regular meals can help reduce the risk of Glimepiride-associated hypoglycaemia.

Swallow the tablet with water. Do not crush or alter the tablet unless the approved product information specifically permits it.

Do not increase the dose or take additional tablets if blood glucose remains elevated. If you miss a dose, follow your healthcare professional’s instructions and do not take a double dose to compensate.

Storage

• Store GLIPDEN-M1 in a cool, dry place.
• Protect the tablets from excessive heat and moisture.
• Keep the tablets away from direct sunlight.
• Keep the tablets in their original BLISTER packaging until use.
• Keep out of the sight and reach of children.
• Do not use the product after the expiry date printed on the packaging.